Hoth Therapeutics
Hoth Therapeutics is dedicated to developing innovative, impactful, and ground-breaking treatments to improve patient quality of life. They focus on early-stage pharmaceutical research and development, collaborating with scientists, clinicians, and key opinion leaders to seek out and investigate promising medications. Their mission is driven by a patient-centric approach, aiming to create breakthroughs and diversify treatment options across various therapeutic areas including oncology, neurology, inflammatory diseases, dermatology, and medical devices.
Industries
Nr. of Employees
small (1-50)
Hoth Therapeutics
New York, New York, United States, North America
Patents
Products
HT-001 Gel
Topical treatment undergoing Phase 2a clinical trial for evaluation of safety, preliminary efficacy, and pharmacokinetics in adult subjects and patients on EGFR inhibitor therapy.
HT-KIT Injection
HT-KIT is a New Molecular Entity classified as an Antisense Oligonucleotide (ASO) that directly targets and inhibits the proto-oncogene c-KIT.
BioLexa
Topical treatment undergoing Phase 1b clinical trial to evaluate safety, tolerability, pharmacokinetics, and efficacy of twice-daily application in adult healthy subjects and patients with mild to moderate atopic dermatitis.
HT-004
HT-004 is an Antisense oligonucleotide (ASO) under development for treatment of IgE-mediated allergies and asthma maintenance therapy, targeting FcεRIβ via alternative splicing.
HT-001 Gel
Topical treatment undergoing Phase 2a clinical trial for evaluation of safety, preliminary efficacy, and pharmacokinetics in adult subjects and patients on EGFR inhibitor therapy.
HT-KIT Injection
HT-KIT is a New Molecular Entity classified as an Antisense Oligonucleotide (ASO) that directly targets and inhibits the proto-oncogene c-KIT.
BioLexa
Topical treatment undergoing Phase 1b clinical trial to evaluate safety, tolerability, pharmacokinetics, and efficacy of twice-daily application in adult healthy subjects and patients with mild to moderate atopic dermatitis.
HT-004
HT-004 is an Antisense oligonucleotide (ASO) under development for treatment of IgE-mediated allergies and asthma maintenance therapy, targeting FcεRIβ via alternative splicing.
Services
Collaborative arrangements with academic groups, clinicians, and contract organizations to advance early-stage therapeutic candidates from bench to pre-clinical and early clinical stages.
Support for clinical trial activities and patient-facing programs including expanded access and compassionate use pathways.
Design and execution of pre-clinical studies including behavioral assessments in rodent models and application of in vivo analytical methods for protein kinetics.
Collaborative arrangements with academic groups, clinicians, and contract organizations to advance early-stage therapeutic candidates from bench to pre-clinical and early clinical stages.
Support for clinical trial activities and patient-facing programs including expanded access and compassionate use pathways.
Design and execution of pre-clinical studies including behavioral assessments in rodent models and application of in vivo analytical methods for protein kinetics.
Expertise Areas
- Early-stage drug development
- Pre-clinical pharmacology and animal models
- Translational research
- Neurodegenerative disease research
Key Technologies
- Micro-immunoelectrode (MIE) technology for in vivo protein measurement
- In vivo microdialysis
- Rodent behavioral assay platforms
- Electrochemical aerosol pathogen detection sensors